|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.95 TWD | -2.34% |
|
+2.34% | -25.53% |
| 07-13 | EirGenix Partner Secures EMA Nod for Breast Cancer Biosimilar Vial | MT |
| 05-27 | Transcenta Secures 7 Million Yuan Milestone Payment Under EirGenix Bio-Platform Deal; Shares Fall 7% | MT |
| Market Cap | 13.92B 430M 377M 351M 323M 606M 41.07B 616M 4.17B 1.63B 20.37B 1.61B 1.58B 70.37B | P/E 2026 * |
-30.2x | P/E 2027 * | 80.6x |
|---|---|---|---|---|---|
| Enterprise Value | 12.67B 391M 343M 320M 294M 551M 37.39B 561M 3.79B 1.49B 18.54B 1.47B 1.44B 64.06B | EV / Sales 2026 * |
8.6x | EV / Sales 2027 * | 5.58x |
| Free-Float |
60% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -2.34% | ||
| 1 week | +2.34% | ||
| Current month | -7.92% | ||
| 1 month | -0.33% | ||
| 3 months | -0.33% | ||
| 6 months | -29.63% | ||
| Current year | -25.53% |
| 1 week | 45.2 |  | 47.45 |
| 1 month | 44.3 | | 53.6 |
| Current year | 40.15 | | 67.6 |
| 1 year | 40.15 | | 84.3 |
| 3 years | 40.15 | | 111 |
| 5 years | 40.15 | | 163.5 |
| 10 years | 21.55 | | 195 |
| Manager | Title | Age | Since |
|---|---|---|---|
Li Cheng Liu
CEO | Chief Executive Officer | - | 01/04/2013 |
Hsiu Chuan Yang
DFI | Director of Finance/CFO | - | 03/05/2016 |
Yu Wen Liu
PRN | Corporate Officer/Principal | - | 20/05/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
BRD | Director/Board Member | - | 14/06/2013 |
Hsiu Hui Chen
BRD | Director/Board Member | - | 13/09/2016 |
Li Cheng Liu
CHM | Chairman | - | 10/06/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.34% | +2.34% | -31.93% | -57.06% | 441M | |
| +3.41% | +1.90% | +23.16% | -7.79% | 67.88B | |
| +1.79% | +2.58% | +39.89% | +213.85% | 53.23B | |
| +0.26% | +54.90% | +54.90% | +54.90% | 48.71B | |
| +2.69% | -2.52% | -55.39% | -55.35% | 38.98B | |
| +2.07% | +0.50% | +57.93% | -23.02% | 29.55B | |
| +10.98% | +11.17% | +86.00% | +106.85% | 23.75B | |
| -0.19% | -7.29% | +63.11% | -53.39% | 22.07B | |
| +0.62% | -2.81% | +0.84% | +162.10% | 19.84B | |
| +0.60% | +0.39% | +65.65% | +126.60% | 16.57B | |
| Average | +1.98% | +0.22% | +30.42% | +46.77% | 32.1B | |
| Weighted average by Cap. | +2.44% | +1.30% | +32.55% | +54.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.47B 45.53M 39.96M 37.21M 34.22M 64.15M 4.35B 65.25M 441M 173M 2.16B 171M 167M 7.45B | 2.34B 72.37M 63.51M 59.14M 54.4M 102M 6.91B 104M 702M 275M 3.43B 272M 266M 11.85B |
| Net income | -458M -14.15M -12.42M -11.56M -10.63M -19.93M -1.35B -20.28M -137M -53.69M -670M -53.11M -51.96M -2.32B | 172M 5.31M 4.66M 4.34M 3.99M 7.49M 508M 7.61M 51.51M 20.16M 252M 19.95M 19.51M 870M |
| Net Debt | -1.25B -38.52M -33.8M -31.48M -28.95M -54.27M -3.68B -55.2M -373M -146M -1.82B -145M -141M -6.31B | -838M -25.88M -22.72M -21.15M -19.46M -36.47M -2.47B -37.1M -251M -98.23M -1.23B -97.17M -95.08M -4.24B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/07/26 | NT$45.95 | -2.34% | 449,163 |
| 27/07/26 | NT$47.05 | +3.18% | 624,959 |
| 24/07/26 | NT$45.60 | 0.00% | 276,811 |
| 23/07/26 | NT$45.60 | -2.15% | 448,098 |
| 22/07/26 | NT$46.60 | +2.42% | 478,033 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 6589 Stock
Select your edition
All financial news and data tailored to specific country editions
